-
2024-519188-17-00
1
2025-10-07
Relapsed/refractory malignancy with documented diagnosis of human epid
-
2024-515682-34-00
5
2025-10-06
Chronic migraine
-
2024-515715-22-00
5
2025-10-06
Episodic migraine
-
2024-517632-22-00
5
2025-10-06
Hidradenitis Suppurativa
-
2024-519445-29-00
1
2025-10-02
Solid Tumors
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-518015-19-00
4
2025-09-24
Colorectal Cancer
-
2025-520740-16-00
5
2025-09-19
Primary Aldosteronism defined by excess aldosterone secretion
-
2025-520762-22-00
4
2025-09-16
Patients with HR-positive, HER2-negative, non-metastatic node positive
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-516412-17-00
5
2025-08-26
Developmental and Epileptic Encephalopathies (DEE)
-
2024-518761-10-00
4
2025-08-25
Non-small Cell Lung Cancer
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2024-517972-39-00
5
2025-08-19
Autoimmune haemolytic anaemia
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2024-518893-15-00
5
2025-07-29
Chronic lymphotic leukemia and Small Lymphocytic lymphoma
-
2023-503634-50-01
5
2025-07-22
Anemia in patients with chronic kidney disease on dialysis
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-517789-41-00
6
2025-07-04
metastatic or locally advanced renal cell carcinoma